Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer

NCT ID: NCT02483104

Last Updated: 2017-11-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 9 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-07-31
• Study Completion Date: 2016-07-31

Brief Summary

This is a Phase 1, open-label, multicenter, dose escalation study evaluating the tolerability, safety, pharmacokinetics and preliminary efficacy of veliparib in combination with carboplatin and weekly paclitaxel in Japanese subjects with ovarian cancer.

Conditions

Ovarian Cancer

Keywords

ABT-888; BRCA; Primary peritoneal cancer; carboplatin; Fallopian tube; Poly (ADP-ribose) polymerase (PARP); paclitaxel; Ovarian cancer; veliparib

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

veliparib (ABT-888)

Group Type: EXPERIMENTAL

veliparib

Intervention Type: DRUG

Veliparib will be given orally, twice daily on Days 1-21, every 21 days.

carboplatin

Intervention Type: DRUG

Carboplatin will be administered on Day 1 of each cycle, intravenously.

paclitaxel

Intervention Type: DRUG

Paclitaxel will be administered on Days 1, 8, 15 of each cycle, intravenously.

Interventions

veliparib

Veliparib will be given orally, twice daily on Days 1-21, every 21 days.

Intervention Type: DRUG

carboplatin

Carboplatin will be administered on Day 1 of each cycle, intravenously.

Intervention Type: DRUG

paclitaxel

Paclitaxel will be administered on Days 1, 8, 15 of each cycle, intravenously.

Intervention Type: DRUG

Other Intervention Names

ABT-888; paraplatin; taxol

Eligibility Criteria

Inclusion Criteria

Histologically or cytologically confirmed epithelial ovarian, fallopian tube or primary peritoneal carcinoma the International Federation of Gynecology and Obstetrics (FIGO) Stage IC - IV with either optimal (< 1 cm residual disease) or suboptimal residual disease.

Participants must be newly diagnosed, chemotherapy-naïve, and entered between 1 and 12 weeks after initial cytoreductive surgery.

Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1.

Adequate organ and marrow function.

Ability to swallow and retain oral medication, and no uncontrolled emesis.

Women of childbearing potential (except vasectomized partner of female subjects) must agree to use adequate contraception prior to study entry, for the duration of study participation and up to 3 months following completion of therapy. Women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to the study entry. Post menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.

Exclusion Criteria

A history of another invasive cancer within the past 3 years, except non-melanoma skin cancer or in situ malignancies that are considered cured by the investigator (e.g., cervical cancer in situ, in situ carcinoma of the bladder, or breast carcinoma in situ).

Participants who received prior radiotherapy to any portion of the abdominal cavity or pelvis.

Participants who received prior chemotherapy for any abdominal or pelvic tumor.

Any investigational agents less than 4 weeks prior to study enrollment.

Any anti-cancer Chinese medicine/herbal remedies within 14 days prior to study enrollment.

Known history of allergic reaction to Cremophor-paclitaxel, carboplatin, Azo Colourant Tartrazine (also known as FD&C Yellow 5 or E102), Azo Colourant Orange Yellow-S (also known as FD&C Yellow 6 or E110) or known contraindications to any study supplied drug.

Patients with history or evidence upon physical examination of central nervous system disease, including primary brain tumor, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) within 6 months of the first date of treatment on this study.

Prior therapy with a Poly-(ADP-ribose)-Polymerase (PARP) inhibitor.

Subject has a clinically significant uncontrolled condition(s), including but not limited to:

• Uncontrolled seizure disorder, or focal or generalized seizure within the last 12 months;
• Active infection that requires parenteral antibiotics;
• Known active hepatitis B or hepatitis C with abnormal liver function test or organ dysfunction;
• Symptomatic congestive heart failure; unstable angina pectoris; serious ventricular cardiac arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation) or serious cardiac arrhythmia requiring medication (this does not include asymptomatic atrial fibrillation with controlled ventricular rate); or myocardial infarction within the last 6 months;
• Uncontrolled hypertension (sustained systolic blood pressure > 150 mmHg or diastolic pressure > 100 mmHg despite optimal medical management);
• Bowel obstruction or gastric outlet obstruction;
• Psychiatric illness/social situations that would limit compliance with study requirements;
• Any medical condition which in the opinion of the Investigator places the subject at an unacceptably high risk for toxicities.

Pregnant or lactating.

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 99 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

AbbVie

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Hideyuki Hashiba, BS

Role: STUDY_DIRECTOR

AbbVie

Locations

Site Reference ID/Investigator# 128815

Kurume-shi,Fukuoka, , Japan

Site Reference ID/Investigator# 128997

Morioka, , Japan

Site Reference ID/Investigator# 128058

Nagaizumi-cho, , Japan

Countries

Japan

References

Nishio S, Takekuma M, Takeuchi S, Kawano K, Tsuda N, Tasaki K, Takahashi N, Abe M, Tanaka A, Nagasawa T, Shoji T, Xiong H, Nuthalapati S, Leahy T, Hashiba H, Kiriyama T, Komarnitsky P, Hirashima Y, Ushijima K. Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer. Cancer Sci. 2017 Nov;108(11):2213-2220. doi: 10.1111/cas.13381. Epub 2017 Sep 18.

Reference Type: RESULT

PMID: 28837250 (View on PubMed)

Other Identifiers

M14-488

Identifier Type: -

Identifier Source: org_study_id